[1] Honore PM, Jacobs R, Joannes-Boyau O, et al. Newly designed CRRT membranes for sepsis and SIRS-a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review[J]. ASAIO J, 2013,59(2):99-106. [2] Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012[J]. Intensive Care Med, 2013,39(2):165-228. [3] Luan YY,Dong N,Xie M,et al.Thesignificanace and regulatory mechanisms of innate immune cells in the development of sepsis [J].Interferon Cytonkine Res,2014,34(1):2-15. [4] 黄鹤,田昭涛,黎檀实.脓毒症免疫调节机制研究进展[J].中华实验外科杂志,2016,33(3):841-845. [5] LaszloI,Trasy D,Molnar Z,et al.Sepsis:From Pathophysiology to Individualized Patient Care[J].J Immunol Res,2015,2015:510436. [6] Lekkou A,Kamkantza M,Mouzaki A,et a1.Cytokine production and monocyte HLR-DR expression as predictors of outcome for patients with conmmunity acquired severe infections[J].Clin Diagn Lab Immunol,2004, 11:161-167. [7] 苏磊,周殿元,唐柚青,等.CDl4+单核细胞人自细胞DR抗原在脓毒症早期监测中的临床意义[J].中国危重病急救医学,2006,ll(18):677-679. [8] 周立新,李轶男,誉铁鸥,等.重度脓毒症患者单核细胞HLA-DR水平与预后的关系[J].广东医学, 2009,30(5):730-732. [9] Honore PM, Jacobs R, Joannes-Boyau O, et al. Con: Dialy- and continuous renal replacement (CRRT) trauma during renal replacement therapy: still under-recognized but on the way to better diagnostic understanding and prevention[J]. Nephrol Dial Transplant, 2013,28(11):2723-2727. [10] Bauer SR, Salem C, Connor MJ Jr, et al. Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT[J]. Clin J Am SocNephrol, 2012,7(3):452-7. [11] Bagshaw SM,Uchino S, BellomoR,et al.Timing of renal replacement therapy and clinical outcomes in critically ill patients with severe acute kidney injury[J].J Crit care,2009,24(1):129-140. [12] Ronco C,BellomoR.Acute renal failure and multiple organ dysfunction in the ICU:from renal replacement therapy (RRT) to multiple organ support therapy (MOST)[J].Int J Artif Organ,2002,25(8):733-747. [13] Kellum J A,LameireN.Diagnosis, evaluation, and management of acute kidney injury:a KDIGO summary (Part 1)[J].Crit Care, 2013,17(1):204. [14] Tian H,Sun T,Hao D,et al.The optimal timing of continuous renal replacement therapy for patients with sepsis-induced acute kidney injury [J].IntUrolNephrol,2014,46(10):2009-2014. [15] Baek SD, Yu H, Shin S,et al. Early continuous renal replacement therapy in septic acute kidney injury could be defined by its initiation within 24 hours of vasopressor infusion. Journal of critical care,2017,39:108-114. [16] Perez-Fernandez X, Sabater-Riera J, Sileanu FE,et al. Clinical variables associated with poor outcome from sepsis-associated acute kidney injury and the relationship with timing of initiation of renal replacement therapy. Journal of critical care,2017,40:154-60. [17] Lee JH, Kim HY, Bae EH, et al. Biomarkers Predicting Survival of Sepsis Patients Treated with Continuous Renal Replacement Therapy. Chonnam medical journal. 2017,53(1):64-8. [18] 王海波,徐丽娟,李克鹏,等.KDIGO标准APACHE II与SOFA评分对脓毒症急性肾损伤患者的预后评估[J].中国急救医学,2013,33(6):499-502. [19] Doi K. Role of kidney injury in sepsis. Journal of intensive care. 2016,4:17. [20] 唐小宇.脓毒血症急性肾损伤患者行连续性肾脏替代治疗的时机和疗效[J].内科急危重症杂志, 2016,(22):137-139. |